-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Luye Pharma’s self-developed innovative anti-tumor preparation, Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005), has been accepted for marketing in China in the treatment of prostate cancer, and it is expected to become the only goserelin in the world.
As the first echelon of leading innovative pharmaceutical companies, Luye Pharma joined 15 other innovative pharmaceutical companies in the listed company roadshow session of the 6th China Pharmaceutical Innovation and Investment Conference this year, attracting many experts, scholars and investment elites
Yang Liang, Vice President of Investor Relations and Public Relations of Luye Pharma, focused on Luye Pharma's global development strategy, innovative drug R&D progress, product market situation, and detailed the progress of key pipelines, global business system in his communication with investors.
Yang Liang, Vice President of Investor Relations and Public Relations, Luye Pharma
Yang Liang said that the current Luye Pharma is at a critical turning point
It is reported that Luye Pharma’s international business operation system has expanded to more than 80 countries and regions around the world, with more than 30 marketed products covering the central nervous system, anti-tumor, cardiovascular and other fields, and business covering major global pharmaceuticals in China, the United States, Europe, and Japan.
Yang Liang said that Luye Pharma adheres to the strategy of "innovation" and "internationalization", and has been accelerating the clinical and launch progress of key research projects, and systematically building an international business system
Relying on the advantages of the world's leading microsphere technology platform, Luye Pharma is deeply involved in major diseases such as oncology and central nervous system.
Also, in the past year
Yang Liang said that various complex factors such as the international environment, economic cycle, industrial structure and the spread of the epidemic are intertwined, making the future prospects face huge uncertainties
